WO2007034279A3 - C3a antagonists and pharmaceutical compositions thereof - Google Patents

C3a antagonists and pharmaceutical compositions thereof Download PDF

Info

Publication number
WO2007034279A3
WO2007034279A3 PCT/IB2006/002563 IB2006002563W WO2007034279A3 WO 2007034279 A3 WO2007034279 A3 WO 2007034279A3 IB 2006002563 W IB2006002563 W IB 2006002563W WO 2007034279 A3 WO2007034279 A3 WO 2007034279A3
Authority
WO
WIPO (PCT)
Prior art keywords
antagonists
pharmaceutical compositions
treating
variety
useful
Prior art date
Application number
PCT/IB2006/002563
Other languages
French (fr)
Other versions
WO2007034279A2 (en
Inventor
Bertrand Leo Chenard
Ann Sorrentino Wright
Original Assignee
Pfizer Prod Inc
Bertrand Leo Chenard
Ann Sorrentino Wright
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, Bertrand Leo Chenard, Ann Sorrentino Wright filed Critical Pfizer Prod Inc
Publication of WO2007034279A2 publication Critical patent/WO2007034279A2/en
Publication of WO2007034279A3 publication Critical patent/WO2007034279A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Aryl substituted pyrazole compounds according to the formula (I) or pharmaceutically acceptable salts thereof, are provided. These compounds are useful in pharmaceutical compositions as C3a antagonists for treating a variety of medical conditions associated with the Complement cascade. Methods for treating such conditions are also provided.
PCT/IB2006/002563 2005-09-19 2006-09-17 C3a antagonists and pharmaceutical compositions thereof WO2007034279A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71853805P 2005-09-19 2005-09-19
US60/718,538 2005-09-19

Publications (2)

Publication Number Publication Date
WO2007034279A2 WO2007034279A2 (en) 2007-03-29
WO2007034279A3 true WO2007034279A3 (en) 2007-07-12

Family

ID=37794373

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/002563 WO2007034279A2 (en) 2005-09-19 2006-09-17 C3a antagonists and pharmaceutical compositions thereof

Country Status (1)

Country Link
WO (1) WO2007034279A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7206132B2 (en) 2018-03-01 2023-01-17 日本たばこ産業株式会社 Methyllactam ring compound and pharmaceutical use thereof

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008253311A1 (en) 2007-05-18 2008-11-27 Bayer Schering Pharma Aktiengesellshaft Inhibitors of hypoxia inducible factor (HIF) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
DE102008057364A1 (en) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft New pyridyl or phenyl ring containing compounds are hypoxia-inducible factor regulation pathway modulators, useful to treat and/or prevent e.g. cancer or tumor diseases, heart attack, arrhythmia, stroke, psoriasis and diabetic retinopathy
DE102009041242A1 (en) 2009-09-11 2011-12-15 Bayer Schering Pharma Aktiengesellschaft New heterocyclically substituted aryl compounds are hypoxia-inducible factor inhibitors useful to treat and/or prevent e.g. cancer or tumor diseases, ischemic cardiovascular diseases, heart attack, arrhythmia, stroke, and psoriasis
DE102008057343A1 (en) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft New phenyl or pyridyl ring containing compounds are hypoxia-inducible factor regulation pathway modulators, useful to treat and/or prevent e.g. cancer or tumor diseases, heart attack, arrhythmia, stroke, psoriasis and diabetic retinopathy
DE102009041241A1 (en) 2009-09-11 2011-08-04 Bayer Schering Pharma Aktiengesellschaft, 13353 New heteroaromatic compounds are hypoxia-inducible factor inhibitors useful to treat and/or prevent e.g. cancer or tumor diseases, heart attack, arrhythmia, stroke, psoriasis, diabetic retinopathy, rheumatoid arthritis and polycythemia
DE102008057344A1 (en) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Aminoalkyl-substituted aryl compounds and their use
AR087701A1 (en) * 2011-08-31 2014-04-09 Japan Tobacco Inc PIRAZOL DERIVATIVES WITH SGLT1 INHIBITING ACTIVITY
JP6378630B2 (en) 2012-03-02 2018-08-22 ラレキサー セラピューティクス，インク Liver X receptor (LXR) modulators for the treatment of skin diseases, disorders, and abnormalities
JP6052673B2 (en) * 2013-04-25 2016-12-27 富士フイルム株式会社 Pyrazole derivatives or salts thereof and pharmaceutical compositions containing them
CA2923178A1 (en) 2013-09-04 2015-03-12 Alexar Therapeutics, Inc. Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions
EP3041835B1 (en) * 2013-09-04 2020-04-08 Ellora Therapeutics, Inc. Liver x receptor (lxr) modulators
CA3089092A1 (en) 2018-04-04 2019-10-10 Japan Tobacco Inc. Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1052238A1 (en) * 1998-01-28 2000-11-15 Shionogi & Co., Ltd. Novel tricyclic compound
WO2004092140A1 (en) * 2003-04-03 2004-10-28 Merck & Co., Inc. Biaryl substituted pyrazoles as sodium channel blockers
WO2005002576A2 (en) * 2003-07-03 2005-01-13 Astex Therapeutics Limited Imidazole derivatives and their use as protein kinases inhibitors
WO2005009435A1 (en) * 2003-07-25 2005-02-03 Pfizer Inc. Aminopyrazole compounds and use as chk1 inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1052238A1 (en) * 1998-01-28 2000-11-15 Shionogi & Co., Ltd. Novel tricyclic compound
WO2004092140A1 (en) * 2003-04-03 2004-10-28 Merck & Co., Inc. Biaryl substituted pyrazoles as sodium channel blockers
WO2005002576A2 (en) * 2003-07-03 2005-01-13 Astex Therapeutics Limited Imidazole derivatives and their use as protein kinases inhibitors
WO2005009435A1 (en) * 2003-07-25 2005-02-03 Pfizer Inc. Aminopyrazole compounds and use as chk1 inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BERNARD ET AL: "AZOLES. PART 25. ISOMERIC 3- AND 5-AMINOPYRAZOLE DERIVATIVES", PHARMAZIE, DIE, GOVI VERLAG, ESCHBORN, DE, vol. 44, no. 8, 1989, pages 535 - 539, XP001249331, ISSN: 0031-7144 *
DUTTA ET AL: "HOMO- AND HETERO-DINUCLEAR METAL COMPLEXES OF BRIDGING LIGANDS CONTAINING PHENOL AND AZOLE MOIETIES. STRUCTURE, SPECTROSCOPY, ELECTROCHEMISTRY AND MAGNETOCHEMISTRY", JOURNAL OF THE CHEMICAL SOCIETY, DALTON TRANSACTIONS, CHEMICAL SOCIETY. LETCHWORTH, GB, no. 11, 1996, pages 2371 - 2379, XP009080277, ISSN: 1472-7773 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7206132B2 (en) 2018-03-01 2023-01-17 日本たばこ産業株式会社 Methyllactam ring compound and pharmaceutical use thereof

Also Published As

Publication number Publication date
WO2007034279A2 (en) 2007-03-29

Similar Documents

Publication Publication Date Title
WO2007034279A3 (en) C3a antagonists and pharmaceutical compositions thereof
WO2007107470A3 (en) Pyrazoles as 11-beta-hsd-1
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
WO2007060140A3 (en) Inhibitors of diacyglycerol acyltransferase (dgat)
MX2007012212A (en) Pyrazoles.
WO2007032028A8 (en) Thiazolinones and oxazolinones and their use as ptp1b inhibitors
WO2009155121A3 (en) Inhibitors of pi3 kinase
WO2007135527A3 (en) Benzimidazolyl compounds
WO2009010416A3 (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
WO2007034282A3 (en) Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists
WO2007096151A3 (en) Inhibitors of p38-kinase for treatment of pulmonary hypertension
WO2006095159A8 (en) (imidazolo-5-yl)-2-anilo-pyrimidines as agents for the inhibition of cell proliferation
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
DE602006009095D1 (en) Diacylglycerol-acyltransferase-hemmer
WO2008000483A3 (en) Phenol derivatives for the treatment of respiratory diseases
WO2008075068A3 (en) Acylaminopyrazoles as fgfr inhibitors
WO2005082892A3 (en) Triazole compounds as antibacterial agents and pharmaceutical compositions containing them
WO2008142055A3 (en) Antiviral agents
WO2006100082A3 (en) Substituted oxindol derivatives, drugs containing said derivatives and the use thereof
WO2008006795A3 (en) Indole compounds
TW200626158A (en) Naphthaline derivatives
WO2006077024A3 (en) 5-aminoindole derivatives
WO2008048589A3 (en) Compounds and methods for treatment of hcv
MX2007006387A (en) 3-substituted pyridine derivatives as h3 antagonists.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06808852

Country of ref document: EP

Kind code of ref document: A2